Sign up


Match Document Document Title
8871718 Transglutaminase inhibitors and methods of use thereof  
Transglutaminase inhibitors and methods of use thereof are provided.
8871708 Compositions and methods for treating AIDS or cancer by inhibiting the secretion of microparticles  
Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also...
8871725 Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs  
This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer...
8871720 Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus  
Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers,...
8871818 Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method  
The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or...
8871721 Methods for inhibiting peritoneal dissemination of cancer cells  
A pharmaceutical composition for treating or preventing peritoneal dissemination is provided. The pharmaceutical composition includes an effective dose of connective tissue growth factor (CTGF) and...
8871719 Modified MELK peptides and vaccines containing the same  
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T...
8865653 Method of treatment for immunogenic treatment resistant cancer  
The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility...
8865764 Compounds and methods for the treatment of cancer  
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin,...
8865642 Natural plant products for control of cancer metastasis  
The invention provides compositions comprising soluble extracts or isolated polypeptides from the edible roots of the plant Colocasia, such as Colocasia esculenta, commonly known as Taro, and from...
8865646 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging  
The present invention relates to dietary compositions comprising reduced level of methionine, tryptophan, all amino acids, or protein, dietary compositions comprising glycerol as a substitute for...
8865652 Method of treating solid cancers with pegylated IL-10  
Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.
8859723 Peptidomimetic macrocycles  
The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.
8859504 Boronate ester compounds and pharmaceutical compositions thereof  
The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of...
8859503 Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity  
This invention provides methods of treating, reducing the incidence of, and inhibiting metastasis formation of carcinomas, sarcomas, Epstein-Barr virus-induced malignancies, B cell proliferative...
8859488 Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response  
The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for ...
8859502 Therapy for MLL-rearranged leukemia  
Provided are methods for treating MLL-rearranged ALL by administering to a patient an HDAC inhibitor alone or in combination with a DNA demethylating agent. Also provided are methods of treating...
8852630 Chimeric small molecules for the recruitment of antibodies to cancer cells  
The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The...
8853151 Pro-drug complexes and related methods of use  
The present invention provides methods, compositions and applications for efficient, site-specific drug delivery using pro-drug complexes comprising one or more functional groups (e.g., imaging...
8853154 Fibronectin based scaffold domain proteins that bind to myostatin  
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat...
8853217 Compounds useful as inhibitors of ATR kinase  
The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this...
8846686 Compounds useful as inhibitors of ATR kinase  
The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this...
8846623 Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis  
Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates...
8846771 Compositions and methods of delivery of pharmacological agents  
The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human...
8841256 P2X7: inhibition of epithelial cancers and papillomas  
The present invention demonstrates that P2X7 receptor induced apoptosis may be specific for cancerous cells. Treatment with the P2X7 ligand BzATP, increased cellular apoptosis with no associated...
8841414 Targeted delivery of therapeutic peptides by thermally responsive biopolymers  
A compound including a cell penetrating peptide (CPP), an elastin-like polypeptide (ELP), and a therapeutic peptide (TP) can be preferentially directed to a target site by applying hyperthermia....
8840878 Peptidomimetic sulfamide compounds and antiviral uses thereof  
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
8841251 Method for making a homogenous vaccine composition comprising a conjugate of EGF and 64K for the treatment of tumors  
A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a...
8840886 Method of treating cancer with DLL4 antagonist and chemotherapeutic agent  
The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that...
8841257 Inhibitors of STAT3 and uses thereof  
Compounds which inhibit the activity of signal transducer and activator of transcription 3 (STAT3) are provided together with methods of making and using the same. The compounds are designed to...
8840874 Vascular delivery systems  
The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the...
8840902 Tumor vaccination involving a humoral immune response against self-proteins  
The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an...
8835394 Treatment for basal cell carcinoma  
The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating...
8834876 Therapeutic agent for hematopoietic tumors  
An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as w...
8828417 Bioactive coating for an implantable device or bioprosthesis  
For an implantable device intended for use in the human body an in-vivo colonization with autologous cells is often desired. The devices, especially prosthetic devices like implant tissues, grafts,...
8828391 Method for EGFR directed combination treatment of non-small cell lung cancer  
The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine...
8828381 Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas  
A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose...
8828685 Monomeric forms of human aminoacyl-t-RNA synthetases having non-canonical biological activities  
Isolated monomelic aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
8828944 Compounds and uses thereof to induce an immunogenic cancer cell death in a subject  
The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility...
8828957 Methods for generating immunity to antigen  
Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a...
8822442 Somatostatin-dopamine chimeric analogs  
The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.
8821883 Method of treating B cell cancers by administering truncated BAFF receptors  
The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also...
8822421 E2F as a target of hormone refractory prostate cancer  
The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also...
8821872 Identification and characterization of a specific CCK-C receptor antibody for human pancreatic cancer and its use for early detection and staging of pancreatic cancer  
Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this...
8822419 Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells  
An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and...
8822420 Peptides and aptamers thereof as specific modulators of mutant p53 function  
In the present application isolated peptides and aptamers thereof able to interact with structural and conformational p53 mutants within the region of the wild-type p53 DNA binding core domain...
8822422 Antitumor agent  
An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor...
8821867 4-1BB binding molecules  
The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic...
8815804 Methods and compositions related to targeting tumors and wounds  
Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to...
8815805 Formulations having an antagonist of α5β1 for anti-angiogenesis and cancer treatment  
The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α...